Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17132448 | SYNTHETIC RIG-I-LIKE RECEPTOR AGONISTS | December 2020 | December 2023 | Allow | 36 | 2 | 1 | No | No |
| 17128320 | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | December 2020 | May 2021 | Allow | 4 | 1 | 0 | No | No |
| 17127664 | P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION | December 2020 | May 2024 | Allow | 41 | 1 | 0 | No | No |
| 17125245 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF COMPLEMENT COMPONENT 5(C5) BY DOUBLE-STRANDED RNA | December 2020 | April 2023 | Allow | 28 | 1 | 0 | No | No |
| 17116214 | COMPOSITIONS AND METHODS FOR TARGETING GLYPICAN-2 IN THE TREATMENT OF CANCER | December 2020 | January 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17247265 | Nucleic Acid Molecules and Uses Thereof | December 2020 | October 2023 | Allow | 34 | 1 | 1 | No | No |
| 16949980 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | November 2020 | May 2024 | Allow | 42 | 1 | 0 | No | No |
| 17055888 | AAV SEROTYPES FOR BRAIN SPECIFIC PAYLOAD DELIVERY | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17097695 | METHODS AND COMPOSITIONS FOR INHIBITING NECROPTOSIS IN NEUROVASCULAR AND/OR NEURODEGENERATIVE DISEASES OR DISORDERS | November 2020 | November 2023 | Abandon | 36 | 2 | 1 | No | No |
| 17094724 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | November 2020 | June 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17053193 | MATERIALS AND METHODS FOR THE DELIVERY OF THERAPEUTIC NUCLEIC ACIDS TO TISSUES | November 2020 | September 2022 | Allow | 23 | 2 | 1 | No | No |
| 17052610 | FUNCTIONAL LIGANDS TO DICAMBA | November 2020 | January 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17085319 | GIN RECOMBINASE VARIANTS | October 2020 | July 2023 | Allow | 32 | 1 | 0 | No | No |
| 17080771 | RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof | October 2020 | March 2023 | Allow | 28 | 1 | 1 | No | No |
| 17049041 | MICRORNAS AS THERAPEUTIC TARGETS FOR ISCHEMIC STROKE | October 2020 | November 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 17048466 | tRNA/pre-miRNA Compositions and Methods For Treating Hepatocellular Carcinoma | October 2020 | May 2023 | Allow | 30 | 1 | 0 | No | No |
| 17047978 | MRNA Driven Expression of RNA Editors for Treatment of Pathologies | October 2020 | June 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 17070337 | FN3 Domain-siRNA Conjugates and Uses Thereof | October 2020 | May 2023 | Allow | 31 | 1 | 1 | No | No |
| 17067572 | MICRORNA REGULATED EXPRESSION VECTORS, METHODS OF MAKING, AND USES THEREOF | October 2020 | April 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17046478 | MIRNAS FOR TREATMENT AND IN VITRO DIAGNOSIS OF DRUG RESISTANT TUMORS | October 2020 | July 2022 | Allow | 22 | 2 | 1 | Yes | No |
| 17063610 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | October 2020 | March 2023 | Allow | 29 | 2 | 1 | No | No |
| 17043784 | APTAMERS FOR TARGETED ACTIVATION OF T CELL-MEDIATED IMMUNITY | September 2020 | January 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17044028 | METHODS OF MODULATING NKX6.3 | September 2020 | May 2022 | Abandon | 20 | 0 | 1 | No | No |
| 17044237 | Systems, Methods And Composition of Using RNASE III Mutants to Produce sRNA to Control Host Pathogen Infection | September 2020 | January 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17032259 | MICRORNA-BASED LOGIC GATES AND USES THEREOF | September 2020 | June 2022 | Allow | 21 | 1 | 1 | Yes | No |
| 17024100 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | September 2020 | June 2023 | Allow | 33 | 2 | 0 | No | No |
| 17022984 | APTAMERS SPECIFIC FOR TLR-4 AND USES THEREOF | September 2020 | October 2022 | Allow | 25 | 0 | 0 | No | No |
| 17019183 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A MICROBIOME | September 2020 | November 2021 | Allow | 14 | 2 | 1 | Yes | No |
| 17019154 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | September 2020 | February 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 16979777 | MICRO-RNA AND OBESITY | September 2020 | April 2023 | Allow | 31 | 2 | 0 | No | No |
| 16978778 | APPLICATION OF MICRORNA-210 INHIBITOR IN PREPARATION OF DRUGS FOR TREATING INFLAMMATORY SKIN DISEASES | September 2020 | September 2022 | Allow | 25 | 1 | 1 | No | No |
| 16977152 | COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION | September 2020 | September 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 17006003 | Methods of Treating Wounds Using Cathepsin K Inhibitors | August 2020 | June 2023 | Allow | 33 | 2 | 0 | No | No |
| 16971893 | SHORT/SMALL HAIRPIN RNA MOLECULES | August 2020 | April 2024 | Allow | 44 | 5 | 1 | Yes | No |
| 16999948 | IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE | August 2020 | September 2021 | Allow | 13 | 2 | 1 | Yes | No |
| 16996616 | METHODS FOR TREATING BRAIN INJURY | August 2020 | January 2023 | Allow | 29 | 1 | 0 | No | No |
| 16995586 | MICRO-RNA PROFILING, COMPOSITIONS, AND METHODS OF TREATING DISEASES | August 2020 | April 2022 | Allow | 20 | 1 | 0 | No | No |
| 16988391 | MODIFIED OLIGONUCLEOTIDES TARGETING SNPs | August 2020 | October 2023 | Allow | 38 | 2 | 1 | Yes | Yes |
| 16966132 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | July 2020 | July 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 16941028 | TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA | July 2020 | November 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16963914 | METHODS OF TREATING SPINAL MUSCULAR ATROPHY | July 2020 | June 2022 | Allow | 23 | 1 | 1 | No | No |
| 16963772 | Method to enhance the transcription regulation of SUPT4H on genes containing repetitive nucleotide sequences | July 2020 | September 2023 | Allow | 38 | 3 | 1 | Yes | No |
| 16963315 | HIGH EFFICIENCY APTAMER COMPLEX COMPRISING BRANCHED DNA AND APTAMER, AND USE THEREOF | July 2020 | June 2022 | Allow | 23 | 1 | 1 | No | No |
| 16961062 | METHODS FOR PREVENTING GRAFT ISCHEMIA REPERFUSION INJURY DURING EX VIVO MACHINE PERFUSION PRESERVATION | July 2020 | February 2024 | Allow | 43 | 1 | 1 | No | No |
| 16631954 | miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME | June 2020 | May 2022 | Allow | 28 | 2 | 1 | Yes | No |
| 16910237 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | June 2020 | May 2022 | Allow | 23 | 1 | 0 | No | No |
| 16908798 | AAV-BASED TREATMENT OF CHOLESTEROL-RELATED DISORDERS | June 2020 | April 2022 | Allow | 22 | 1 | 0 | No | No |
| 16908313 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | June 2020 | May 2022 | Allow | 23 | 2 | 1 | No | No |
| 16956092 | NUCLEIC ACID CONSTRUCT FOR IN VITRO AND IN VIVO GENE EXPRESSION | June 2020 | October 2022 | Allow | 28 | 2 | 0 | No | No |
| 16902316 | METHODS RELATING TO CIRCULATING TUMOR CELL CLUSTERS AND THE TREATMENT OF CANCER | June 2020 | April 2022 | Allow | 22 | 2 | 1 | No | No |
| 16898849 | ApoCIII and the Treatment and Diagnosis of Diabetes | June 2020 | December 2021 | Abandon | 18 | 1 | 1 | No | No |
| 16897549 | COMPOSITIONS AND METHODS FOR XI CHROMOSOME REACTIVATION | June 2020 | October 2021 | Allow | 17 | 2 | 1 | No | No |
| 16897976 | OLIGONUCLEOTIDE PROBES AND USES THEREOF | June 2020 | January 2022 | Allow | 19 | 1 | 0 | No | No |
| 16770478 | SENILE DEMENTIA TREATMENT FORMULATION AND APPLICATION THEREOF | June 2020 | July 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 16890436 | GLOBIN GENE THERAPY FOR TREATING HEMOGLOBINOPATHIES | June 2020 | April 2023 | Allow | 34 | 1 | 1 | No | No |
| 16889372 | METHOD FOR DETERMINING DECREASE IN FUNCTIONS OF HIPPOCAMPUS BY USING CORRELATION BETWEEN MICRO RNA AND NMDA RECEPTOR, METHOD FOR INHIBITING DECREASE IN FUNCTIONS, AND METHOD FOR SCREENING FOR INHIBITORS OF DECREASE IN FUNCTIONS | June 2020 | March 2022 | Allow | 22 | 2 | 0 | Yes | No |
| 16889470 | MODULATION OF TRANSTHYRETIN EXPRESSION | June 2020 | August 2022 | Allow | 27 | 1 | 1 | No | No |
| 16764640 | KISSPEPTIN 1 (KISS1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | May 2020 | August 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16764307 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | May 2020 | March 2022 | Allow | 22 | 1 | 1 | No | No |
| 16763880 | RUNX1 INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION | May 2020 | April 2023 | Allow | 35 | 2 | 1 | No | No |
| 15930377 | RNA INTERFERENCE IN OCULAR INDICATIONS | May 2020 | October 2022 | Allow | 29 | 1 | 0 | No | No |
| 16870766 | CMV VECTORS COMPRISING MICRORNA RECOGNITION ELEMENTS | May 2020 | November 2022 | Abandon | 30 | 2 | 0 | No | No |
| 16867587 | DETECTION OF MICROBIAL ENDOTOXINS IN ORAL SAMPLES USING APTAMERS | May 2020 | January 2023 | Allow | 32 | 1 | 1 | No | No |
| 16761880 | APTAMER FOR ADAMTS5 AND USE FOR APTAMER FOR ADAMTS5 | May 2020 | July 2022 | Allow | 26 | 1 | 0 | No | No |
| 16867763 | FMRP and Cancer Treatment | May 2020 | May 2022 | Allow | 25 | 2 | 1 | No | No |
| 16761009 | METHODS AND COMPOSITIONS RELATED TO INCREASED ROTAVIRUS PRODUCTION | May 2020 | June 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16761112 | COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | May 2020 | April 2023 | Abandon | 36 | 2 | 1 | No | No |
| 16756988 | METHODS OF EXPRESSING A POLYNUCLEOTIDE OF INTEREST IN THE CONE PHOTORECEPTORS OF A SUBJECT COMPRISING THE SUBRETINAL DELIVERY OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9-DERIVED VECTOR | April 2020 | March 2023 | Allow | 35 | 1 | 1 | No | No |
| 16850355 | APTAMERS BINDING TO LEGIONELLA PNEUMOPHILA | April 2020 | February 2022 | Allow | 22 | 1 | 0 | No | No |
| 16850555 | MODIFIED RNAi AGENTS | April 2020 | March 2022 | Allow | 23 | 2 | 0 | No | No |
| 16756298 | CONTROL OF PLANT PESTS USING RNA MOLECULES | April 2020 | August 2021 | Allow | 16 | 2 | 1 | Yes | No |
| 16756232 | CONTROL OF PLANT PESTS USING RNA MOLECULES | April 2020 | February 2024 | Allow | 46 | 5 | 1 | Yes | No |
| 16848273 | CD133 RELATED TO ANTICANCER AGENT RESISTANCE IN COLON CANCER AND USE THEREOF | April 2020 | December 2022 | Allow | 32 | 1 | 1 | No | No |
| 16842157 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS | April 2020 | November 2021 | Allow | 19 | 1 | 0 | No | No |
| 16840249 | OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION | April 2020 | November 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16650496 | CRISPR/CAS SYSTEM AND METHOD FOR GENOME EDITING AND MODULATING TRANSCRIPTION | March 2020 | July 2023 | Allow | 40 | 2 | 1 | No | No |
| 16649244 | COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASE | March 2020 | July 2022 | Allow | 28 | 0 | 0 | No | No |
| 16825918 | Thiomorpholino Oligonucleotides For The Treatment of Muscular Dystrophy | March 2020 | August 2022 | Allow | 29 | 1 | 1 | No | No |
| 16825284 | DNA APTAMERS, METHOD FOR INHIBITING HUMAN GALECTIN-1 AND METHOD OF TREATING A MAMMAL IN NEED THEREOF | March 2020 | January 2023 | Allow | 34 | 1 | 1 | No | No |
| 16648822 | SPLICE INHIBITING OLIGONUCLEOTIDES | March 2020 | April 2021 | Allow | 13 | 1 | 1 | No | No |
| 16814398 | PREDICTING RESPONSE TO ALVOCIDIB BY MITOCHONDRIAL PROFILING | March 2020 | January 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16811504 | COMPOSITIONS AND PROCESSES FOR TARGETED DELIVERY, EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS IN TISSUE | March 2020 | May 2022 | Allow | 26 | 3 | 1 | Yes | Yes |
| 16810771 | POLYNUCLEOTIDE CONJUGATES AND USES THEREOF | March 2020 | August 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16807577 | TARGETED RNA EDITING | March 2020 | March 2023 | Allow | 36 | 2 | 0 | No | No |
| 16643293 | AN INHIBITOR FOR USE FOR PREVENTING AND/OR TREATING AN INFECTION WITH HEPATITIS B VIRUS | February 2020 | August 2022 | Allow | 30 | 3 | 0 | No | No |
| 16798314 | FUNCTIONAL LIGANDS TO COLISTIN | February 2020 | November 2022 | Allow | 33 | 1 | 1 | No | No |
| 16640856 | METHODS OF CHANGING TRANSCRIPTIONAL OUTPUT | February 2020 | July 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16640213 | MODIFIED POLYNUCLEOTIDE | February 2020 | September 2021 | Allow | 19 | 2 | 1 | Yes | No |
| 16794066 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC FIBROSIS | February 2020 | October 2021 | Allow | 20 | 2 | 1 | Yes | No |
| 16789483 | METHOD FOR DETERMINING DESIRED CELL TYPE USING EXPRESSION OF miRNA AS INDICATOR | February 2020 | December 2021 | Abandon | 22 | 1 | 0 | No | No |
| 16786709 | RNA CONTAINING COMPOSITIONS AND METHODS OF THEIR USE | February 2020 | January 2024 | Abandon | 47 | 3 | 0 | No | No |
| 16636255 | TUNABLE REVERSIR TM COMPOUNDS | February 2020 | March 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16778582 | RNAI AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENAC AND METHODS OF USE | January 2020 | August 2021 | Allow | 19 | 1 | 1 | No | No |
| 16778188 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | January 2020 | August 2021 | Allow | 19 | 1 | 1 | No | No |
| 16777742 | MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS | January 2020 | October 2021 | Abandon | 20 | 1 | 1 | No | No |
| 16750083 | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | January 2020 | January 2022 | Allow | 23 | 1 | 1 | No | No |
| 16749293 | MODULATORY POLYNUCLEOTIDES | January 2020 | August 2021 | Allow | 18 | 1 | 0 | No | No |
| 16746555 | DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS | January 2020 | June 2022 | Allow | 29 | 3 | 1 | No | No |
| 16631866 | PRESYMPTOMATIC MICRO RNA TARGETS FOR TREATMENT OF NEURODEGENERATION PATHOLOGY | January 2020 | March 2021 | Allow | 14 | 2 | 1 | Yes | No |
| 16742741 | COMPOSITIONS AND METHODS FOR INHIBITING FACTOR D | January 2020 | December 2021 | Allow | 23 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WHITEMAN, BRIAN A.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 4.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WHITEMAN, BRIAN A works in Art Unit 1635 and has examined 783 patent applications in our dataset. With an allowance rate of 52.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner WHITEMAN, BRIAN A's allowance rate of 52.7% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WHITEMAN, BRIAN A receive 1.72 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by WHITEMAN, BRIAN A is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +23.2% benefit to allowance rate for applications examined by WHITEMAN, BRIAN A. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.3% of applications are subsequently allowed. This success rate is in the 54% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 56.8% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 74.1% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 95.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 66.4% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 4.9% of allowed cases (in the 86% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.9% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.